Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Jul 02, 2022 4:05am
144 Views
Post# 34797153

RE:RE:Pretty disappointing if you ask me.

RE:RE:Pretty disappointing if you ask me.I think that the PRC Partners analysis was not very helpful.

Sure, I can understand that without actual numbers it's not possible to calculate a proper valuation.But when one don't know, one can always make assumptions and be transparent. The statement of a 10-bagger is not backed up at all. I think it's much more than 10 if the expected anti-aging/anti-wrinkle deal comes true in 2023, but that's another story.

Despite the obvious well-connected writer, it does not support PRC Partners as a serious player.

Nor does the reference to their so called Swedish office give any serious impression. The address combined with the telephone number leads to a beauty salon owner in a mall outside Stockholm!

The part that makes me most nervous though is the reference to institutions and funds that Sirona are in talk with based on the Abbvie deal - will that lead to further dilution or not? That's must be communicated to the market as soon as possible, especially as they obviously have not bought shares on the open market - yet.

The best part of the analysis is that we are informed about the recruitment of a new CEO. The upcoming news release should give the share price a boost and combined with the AbbVie deal turn the page to a new chapter of the company.

<< Previous
Bullboard Posts
Next >>